Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 5, 2006, Pages 874-879

  Ch'ang, Hui Ju ^a   Wang, Chuan Cheng ^a   Cheng, Ann Lii ^b   Hsu, Chiun ^b   Lu, Yen Shen ^b   Chang, Ming Chu ^b   Lin, Jaw Town ^b   Wang, Hsiu Po ^b   Shiah, Her Shyong ^a   Liu, Tsang Wu ^a   Chang, Jang Yang ^a   Whang Peng, Jacqueline ^a   Chen, Li Tzong ^a,c,d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Gemcitabine; Infusional fluorouracil; Oxaliplatin; Pancreatic cancer; Phase I

Indexed keywords

CORTICOSTEROID; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIP; OXALIPLATIN; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 33646900006     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.04022.x     Document Type: Article

References (26)

1. Burris HA Moore MJ Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial JClinOncol 1997 15 2403 13
2. Bruckner HW Zhou G Haenel P et al. Ex vivo ATP tumor testing of gemcitabine for combination chemotherapy and biochemical modulation (Abstract) ProcAmAssocCancer Res 1998 89 2116
3. Oettle H Riess H Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer Cancer 2002 95 4 Suppl. 912 22
4. Shiah HS Cheng AL Hsu C et al. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer J. Gastroenterol. Hepatol. in press
5. Berlin JD Catalano P Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: eastern cooperative oncology group trial e2297 JClinOncol 2002 20 3270 75
6. Di Costanzo F Sdrobolini A Carlini P et al. Gemcitabine (GEM) alone or in combination with 5-FU continuous infusion (CI) in the treatment of advanced pancreatic cancer: a GOIRC randomized phase II trial (Abstract) ProcAmSocClinOncol 2001 20 154a
7. Colucci G Giuliani F Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale Cancer 2002 94 902 10
8. Bramhall SR Schulz J Nemunaitis J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer BrJCancer 2002 87 161 7
9. Van Cutsem E van de Velde H Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer JClinOncol 2004 22 1430 88
10. Kornmann M Fakler H Butzer U Beger HG Link KH Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases Anticancer Res 2000 20 3259 64
11. Raymond E Buquet-Fagot C Djelloul S et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor ag337 in human colon, breast and ovarian cancers Anti-Cancer Drugs 1997 8 876 85
12. Faivre S Raymond E Woynarowski JM Cvitkovic E Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines Cancer ChemotherPharmacol 1999 44 117 23
13. Abbruzzese JL Grunewald R Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine JClinOncol 1991 9 491 8
14. Tempero M Plunkett W Ruiz Van Haperen V et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma JClinOncol 2003 21 3402 8
15. Andre T Bensmaine MA Louvet C et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen JClinOncol 1999 17 3560 68
16. Hsieh RK Chao TY Chen WS et al. Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-fu for pretreated advanced colorectal cancer is effective and not affected by different previous 5-fu regimens Cancer Invest 2004 22 171 9
17. Tempero M Plunkett W Ruiz Van Haperen V et al. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. Fixed dose rate in metastatic pancreatic adenocarcinoma ProcAmSocClinOncol 1999 18 237a
18. Miller AB Hoogstraten B Staquet M Winkler A Reporting results of cancer treatment Cancer 1981 47 207 14
19. Kaplan EL Meier P Nonparametric estimation from incomplete observation JAmStatAssoc 1958 53 457 81
20. Louvet C Andre T Hammel P et al. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM) AnnOncol 2001 12 675 9
21. Chen LT Whang-Peng J Current status of clinical studies for colorectal cancer in Taiwan ClinColorectal Cancer 2004 4 196 203
22. Alberts SR Townley PM Goldberg RM et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study AnnOncol 2003 14 580 85
23. Boxberger F Happich K Schirner I et al. Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma ZGastroenterol 2002 40 881 4
24. Louvet C Labianca R Hammel P et al. Gemox (gemcitabine + oxaliplatin) versus gem (gemcitabine) in non-resectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup phase III JClinOncol 2004 22 Suppl. 14 4008
25. Louvet C Andre T Lledo G et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study JClinOncol 2002 20 1512 18
26. Conroy T Paillot B Francois E et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer - a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study JClinOncol 2005 23 1228 36